Donanemab-AZBT

PHOENIX, Nov. 14, 2024. A new Alzheimer's prevention study has received a $74.5 million five-year grant from the National Institute on Aging, part of the National Institutes of Health (NIH). The two-part study will be conducted in members of the world's largest autosomal dominant Alzheimer's disease (ADAD) kindred in Colombia who carry a genetic mutation that makes them all but destined to develop Alzheimer's and become cognitively impaired at an average age of 44. The study is led by Banner Alzheimer's Institute in Phoenix and the Neurosciences Group at the University of Antioquia (GNA) in Medellin, Colombia. It will initially aim to remove amyloid plaques as completely as possible in cognitively impaired and unimpaired carriers of the presenilin 1 (PSEN1) E280A mutation, and then evaluate different ways to stave off the recurrence of plaque deposits and other ensuing elements of the disease. Enrollment is expected to begin in the fall of 2025. The first part of the study will use Eli Lilly and Company's (Lilly) antibody therapy donanemab to remove existing plaques as completely as possible (i.e., to levels consistent with a negative amyloid PET scan). Donanemab has been shown to clear amyloid plaques and slow cognitive decline, and was recently approved by the U.S. Food and Drug Administration for use in patients with mild cognitive impairment and dementia due to Alzheimer's. The study will provide new information about the drug's safety, tolerability, and biological efficacy in the unimpaired and impaired stages of ADAD. The second part of the study will compare the following approaches in the same participants, for safety, tolerability and ability to avert amyloid plaque accumulation and other biological and clinical features of the disease: This study builds on the history, partnership, infrastructure and learnings of the original API ADAD Colombia Trial, which launched a new era in Alzheimer's prevention research when it was announced by NIH in 2012. While the investigational drug in the original trial with crenezumab failed to clear plaques or demonstrate a clinical benefit, the study introduced paradigms to speed up the evaluation of promising prevention therapies, found ways to do so in a vulnerable population in a developing country, and led to a growing number of prevention trials, some of which may find the first effective Alzheimer's prevention therapies within the next few years. Both the original and the new trial tap into GNA's identification of about 6,000 distant relatives from the Colombian PSEN1 E280A kindred, including about 1,200 who carry the ADAD-causing genetic mutation. "We are excited about the chance to advance the fight against Alzheimer's disease in partnership with our outstanding colleagues and these unique families in Colombia," said Robert Alexander, MD, the API's chief scientific officer and one of the prevention trial leaders. "This study will clarify the extent to which the antibody treatment reduces amyloid plaques in the unimpaired and impaired stages of ADAD and test different approaches to maintain low amyloid levels following plaque removal." The new study will enroll 200 cognitively unimpaired and mildly impaired mutation carriers and 40 non-carriers (who will receive placebo) from the Colombian kindred. "This trial is a testament to our dear friend and longstanding partner, Dr. Francisco Lopera, who established GNA, forged a close working relationship with API, and could not have been more committed to these families," said Eric M. Reiman, MD, executive director of Banner Alzheimer's Institute and one of the other API leaders. "He constantly said, 'My families are waiting,' and he played indispensable roles in the effort to find effective prevention therapies." "I am honored to follow in Dr. Lopera's footsteps and continue our work with API," said David Aguillón, MD, GNA's new director and principal investigator of the University of Antioquia study site. "Dr. Lopera and the Antioquia families have inspired all of us to never give up, to maintain our sense of urgency to find effective Alzheimer's prevention therapies, and to do so in ways that will help our Antioquia families." The research study is supported by grant R01AG086363 from the NIH National Institute on Aging, the lead U.S. federal agency supporting and conducting Alzheimer's disease and related dementias research. Lilly and Roche are generously donating the drug supplies that will be evaluated in this study. The study is led by Drs. Robert Alexander, Eric Reiman and Jessica Langbaum from BAI and its API; David Aguillón from the University of Antioquia; and Yakeel Quiroz from the University of Antioquia and Massachusetts General Hospital. API also received a $3 million grant from the Zurich-based NOMIS Foundation to continue to assess about 2,000 mutation carriers and non-carriers from the PSEN1 E280A kindred, provide a shared resource of longitudinal data and blood samples for the field, accelerate enrollment in the new prevention trial, and provide education and social support for the families irrespective of their participation in the study. About Banner Alzheimer's Institute Since its inception in 2006, Banner Alzheimer's Institute has sought to find effective Alzheimer's disease prevention therapies within twenty years, establish a new model of care for cognitively impaired patients and family caregivers, and forge new models of collaboration in biomedical research. It has made groundbreaking contributions to the unusually early detection, tracking, diagnosis, study and prevention of Alzheimer's disease. It includes the pioneering Alzheimer's Prevention Initiative, an extensive profile of research studies and clinical trials, comprehensive clinical, family and community service programs, leading brain imaging and blood-based biomarker research programs, and strategic partnerships with public and private research organizations around the world. About the Alzheimer's Prevention Initiative The Alzheimer's Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimer's prevention research. Led by Banner Alzheimer's Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimer's disease. API continues to establish brain imaging, fluid biomarker and cognitive endpoints needed to rapidly test promising prevention therapies. It also leads participant recruitment registries to accelerate enrollment into Alzheimer's-focused studies. API is intended to provide the scientific means, accelerated approval pathway and enrollment resources needed to evaluate the range of promising Alzheimer's prevention therapies and find ones that work without losing another generation. For more information, go to alzheimerspreventioninitiative.com. About Grupo de Neurociencias de Antioquia Grupo de Neurociencias de Antioquia (GNA), at the University of Antioquia in Medellín, is ranked as one of the best research organizations in Colombia. For more than three decades, GNA has characterized what is now considered the world's largest population with early-onset familial Alzheimer's disease, and it continues to play pioneering roles in the effort to find effective Alzheimer's prevention therapies. GNA has also characterized large and paradigmatic populations with other forms of dementia and other neurogenetic disorders. SOURCE Banner Alzheimer's Institute Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

全球医疗行业每日重点资讯 文 | 卓悦 企业动态 阿斯利康泰州供应基地可持续发展战略项目在中国医药城正式启动。据悉，2024-2025年期间阿斯利康泰州供应基地计划投资3000万元人民币打造零碳绿色示范企业目标在2026年减少98%的碳排放和40%水资源消耗并将能耗强度降低20%。2012年阿斯利康泰州供应基地落户中国医药城，2014年泰州基地正式投入使用，总投资3亿美金，是迄今阿斯利康在江苏单体投资最大的项目。主要产品有倍他乐克、波依定、帮备安达唐，向中国及世界供应高品质固体口服制剂。 药明生物将扩大德国勒沃库森基地产能，新建一条隔离器灌装预充针生产线。此次扩建将优化基地生产布局，为多产品的CRDMO服务提供更高效的解决方案。该新增产线可以为多种规格的预充针进行灌装(1毫升、2.25毫升和3毫升)，灌装速度最快可达400支/分钟，年产能超过1700万支。目前德国勒沃库森基地已有一条无菌灌装和冻干制剂生产线，年产能达1000万瓶。该新增产线预计将在近期启动建设，2026年达到GMP生产标准。 王雅丽自加入亿腾集团，担任肿瘤事业部北中国销售总监职务，负责肿瘤事业部北中国的销售管理，兼管肿瘤事业部南中国销售和市场医学管理工作。王雅丽拥有25年医药行业销售与市场经验，曾就职于阿斯利康、GSK 等跨国药企，加入亿腾医药之前，是阿斯利康区域销售总监。 天津医药：冯煌任董事长，张旺任副董事长。天津市医药集团有限公司公告，拟选举冯煌、王东、张旺、徐阳雪、王光华为公司董事，陈津竹不再担任公司董事长、董事职务，滕飞不再担任公司副董事长、董事职务，张铭芮、孙利军、于克祥不再担任公司董事职务；选举冯煌担任公司董事长，张旺担任公司副董事长，赵忱担任公司监事会主席。 大冢制药和ICU医疗打造共建联盟供应美国。大冢制药厂将向医疗设备公司ICU medical支付2亿美元，以建立向美国供应静脉注射产品的联盟。该合资企业将拥有17个全球生产基地，每年向美国市场提供约14亿单位的静脉注射药物。根据周二发布的消息，预计将从2025年第二季度开始实施。这两家公司还将开发新的静脉注射药物，ICU称这些产品历来难以获得融资。ICU将推广合资企业开发的任何新药。 全球领先的生命科学投资集团Novo Holdings宣布，其共同牵头了Alentis Therapeutics的1.814亿美元D轮融资。Alentis是一家临床阶段的生物技术公司，总部位于瑞士巴塞尔，正在开发以Claudin-1（CLDN1）为靶点的药物管线。这笔融资将使Alentis能够启动两种首创ADC药物的1/2期临床试验。 爱尔康(Alcon)公布2024年第三季度业绩。季度净销售额和其他营收24.54亿美元，上年同期为23.29亿美元。季度营业利润3.32亿美元，上年同期为2.93亿美元。季度净利润2.63亿美元，上年同期为2.04亿美元。 产业动态 礼来阿尔茨海默病新药Donanemab日本定价获批。日本厚生劳动相的咨询机构“中央社会保险医疗协议会”批准了阿尔茨海默病新药“多奈单抗”的官方定价，一名患者一年的治疗费用约为308万日元。20日起将适用公共保险。该药由美国制药巨头礼来公司研发。 雅培不断引入全球前沿的技术解决方案，助力中国检验医学加速发展；通过持续深入本土化战略，深耕中国满足更广阔的医疗发展需求。旗下两款重磅智能化解决方案——免疫模块 Alinity i 和自动化流水线 GLP，宣布实现中国本地化生产之后，在 11 月 6 日迎来首条国产化流水线 GLP 的正式交付。自动化流水线 GLP 从提升样本周转时间、确保准确临床决策、降低人员工作强度以及充分利用场地空间等多个维度满足实验室日益增长的需求。 参天制药与极目生物就眼科疗法ARVN001开展商业化合作。参天制药与极目生物宣布，极目生物将其正在研发中的ARVN001在中国内地的独家商业化权益授权于参天制药。ARVN001采用脉络膜上腔微注射专利技术，将用于治疗葡萄膜炎性黄斑水肿和其他一些正在开发中的潜在眼科适应症。 联系美通社 +86-10-5953 9500 info@prnasia.com